Structure-Based Design of a Novel Series of Potent, Selective Inhibitors of the Class I Phosphatidylinositol 3-Kinases

Adrian L. Smith(Amgen (United States)), Mark H. Norman(Amgen (United States)), Victor J. Cee(Amgen (United States)), Nuria Tamayo(Amgen (United States)), Raju Subramanian(Gilead Sciences (United States)), Noel D. D’Angelo(Amgen (United States)), Nancy R. Zhang(University of the Arts), Anthony B. Reed(Amgen (United States)), Nobuko Nishimura(Amgen (United States)), Kevin Yang(Revolution Medicines (United States)), Seifu Tadesse(Amgen (United States)), Brian A. Lanman(Harvard University), Leeanne Zalameda(Amgen (United States)), Tisha San Miguel(Amgen (United States)), Douglas A. Whittington(Amgen (United States)), Erin L. Mullady(Amgen (United States)), Claire Jackson(Babraham Institute), Liping H. Pettus(Amgen (United States)), Brad Herberich(Amgen (United States)), Jian Jiang(Xuzhou Medical College), Shon K. Booker(Amgen (United States)), Longbin Liu(National University of Defense Technology), Ling Wang(Guizhou University), Paul E. Hughes(Amgen (United States)), Tian Wu(Guangzhou University of Chinese Medicine), Sean Caenepeel(Amgen (United States)), Kristin L. Andrews(Amgen (United States)), Yunxin Bo(Amgen (United States)), Daniel J. Freeman(Amgen (United States)), John D. McCarter(Amgen (United States)), Fang‐Tsao Hong(Amgen (United States)), Ryan P. Wurz(Amgen (United States))
Journal of Medicinal Chemistry
May 1, 2012
Cited by 50


Related Papers